PTP1B Inhibition: A new target in the treatment of atherosclerosis
Research type
Research Study
Full title
PTP1B Inhibition: A potential new target in the treatment of atherosclerosis.
IRAS ID
187009
Contact name
Dawn Thompson
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
1 years, 4 months, 31 days
Research summary
Obesity is a major risk factor for the development of insulin resistance, diabetes and cardiovascular disease (CVD). CVD is the most prevalent cause of mortality among patients with type-1 or type-2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a strong link between atherosclerosis and insulin resistance, due to impaired insulin receptor (IR) signalling. Moreover, inflammatory cells, in particular macrophages, play a key role in pathogenesis of atherosclerosis and insulin resistance in humans. Thus, modulating macrophage function has potential as a therapeutic target in this spectrum of disorders. As such, we hypothesise that decreasing PTP1B levels in macrophages isolated from patients with clinically relevant peripheral arterial disease (PAD) with and without type 2 diabetes will lead to decreased inflammation and atherosclerosis development potential. To address this we will use genetic and pharmacological tools to decrease PTP1B levels and activity. We propose that our studies will delineate a potential new role for PTP1B inhibitors (which are currently in Phase-II clinical trials) in the treatment of CVD and atherosclerosis.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
15/EE/0475
Date of REC Opinion
18 Jan 2016
REC opinion
Further Information Favourable Opinion